Hodgkin-lymphoma-derived cells show high sensitivity to dactinomycin and paclitaxel. (Q33297034)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17786721%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

title

Hodgkin-lymphoma-derived cells show high sensitivity to dactinomycin and paclitaxel (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17786721%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17786721%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

Laszlo Szekely

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17786721%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

Staffan Eksborg

6

1 reference

ORCID Public Data File 2021

author name string

Lorand Levente Kis

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17786721%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

Gyorgy Stuber

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17786721%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

Emilie Flaberg

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17786721%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

Rita Otvos

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17786721%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

Henriette Skribek

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17786721%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

Eva Olah

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17786721%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

publication date

1 September 2007

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17786721%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17786721%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

volume

48

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17786721%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

issue

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17786721%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

page(s)

1835-1845

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17786721%20AND%20SRC:MED&resulttype=core&format=json

Constitutive nuclear factor-kappaB-RelA activation is required for proliferation and survival of Hodgkin's disease tumor cells

5 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1080%2F10428190701559132

Molecular mechanisms of constitutive NF-kappaB/Rel activation in Hodgkin/Reed-Sternberg cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190701559132

Epstein-Barr virus-associated Hodgkin's disease: epidemiologic characteristics in international data.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190701559132

Phenotype and frequency of Epstein-Barr virus-infected cells in pretreatment blood samples from patients with Hodgkin lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190701559132

Association of TRAF1, TRAF2, and TRAF3 with an Epstein-Barr virus LMP1 domain important for B-lymphocyte transformation: role in NF-kappaB activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190701559132

Constitutive NF-kappaB maintains high expression of a characteristic gene network, including CD40, CD86, and a set of antiapoptotic genes in Hodgkin/Reed-Sternberg cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190701559132

Hodgkin disease: prognostic factors and treatment strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190701559132

Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190701559132

New treatments for Hodgkin's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190701559132

Pleural effusions in hematologic malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190701559132

Two neoplastic cell lines with unique features derived from Hodgkin's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190701559132

Identification of Hodgkin and Reed-Sternberg cell-specific genes by gene expression profiling

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190701559132

Unique polycomb gene expression pattern in Hodgkin's lymphoma and Hodgkin's lymphoma-derived cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190701559132

In vitro EBV-infected subline of KMH2, derived from Hodgkin lymphoma, expresses only EBNA-1, while CD40 ligand and IL-4 induce LMP-1 but not EBNA-2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190701559132

Cytotoxic drug sensitivity of Epstein-Barr virus transformed lymphoblastoid B-cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190701559132

Gemcitabine, epirubicin and paclitaxel: pharmacokinetic and pharmacodynamic interactions in advanced breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190701559132

Effect of highly active antiretroviral therapy (HAART) on pharmacokinetics and pharmacodynamics of doxorubicin in patients with HIV-associated non-Hodgkin's lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190701559132

Phase I and pharmacokinetic study of docetaxel in combination with epirubicin and cyclophosphamide in advanced cancer: dose escalation possible with granulocyte colony-stimulating factor, but not with prophylactic antibiotics.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190701559132

Can severe vincristine neurotoxicity be prevented?

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190701559132

A phase I/II study of infusional vinblastine with the P-glycoprotein antagonist valspodar (PSC 833) in renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190701559132

High-dose methotrexate pharmacokinetics and outcome of children and young adults with osteosarcoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190701559132

Plasma concentrations of 5-fluorouracil and its metabolites in colon cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190701559132

Pharmacokinetics of mitoxantrone, etoposide and cytosine arabinoside in leukemic cells during treatment of acute myelogenous leukemia--relationship to treatment outcome and bone marrow toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190701559132

Antitumour activity and plasma kinetics of bleomycin by continuous and intermittent administration

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190701559132

Pharmacokinetics of dactinomycin in a pediatric patient population: a United Kingdom Children's Cancer Study Group Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190701559132

Phase I trial of the proteasome inhibitor bortezomib in patients with advanced solid tumors with observations in androgen-independent prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190701559132

Pharmacogenetics of cyclophosphamide in patients with hematological malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190701559132

Serious neutropenia in ALL patients treated with L-asparaginase may be avoided by therapeutic monitoring of the enzyme activity in the circulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190701559132

The influence of renal function on hydroxyurea pharmacokinetics in adults with sickle cell disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190701559132

Tumour cytochrome P450 and drug activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190701559132

THE ORIGIN OF HODGKIN AND REED/STERNBERG CELLS IN HODGKIN'S DISEASE

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190701559132